Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

Cell growth of several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell lines with activating BRAF mutations were insensitive, … (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Impact on signalling was measured: ERK signalling by western blot and RAS-G… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Several BRAF mutant cell lines were treated with vemurafenib, A375 (BRAF V600E) was used as a positive control. Two non-small cell cancer cell lines (H1666 and CAL-12T) containing the BRAF G466V mutat… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In the study with a tumour from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumour regression. And in tumour cell… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumor regression. And in tumor cells o… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treatment with Panitumumab and irinotecan cause tumor regression. And in tumor cells … (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. NSCLC cell lines H1666 and CAL-12T bearing the BRAF G466V mutation were sensitive with… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R).

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R).

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In a BRAF-mutation inducible model in the NIH3T3 cell line, class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R) were resistant to vemurafenib but sensitive to MEK-inhibitor trametinib.

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. The melanoma cell line, SK-MEL-264 (BRAF D594G), was sensitive with low IC50 values (<5… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R).

PMID 28783719 · Yao et al., 2017 · Open in CIViC

RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R).

PMID 28783719 · Yao et al., 2017 · Open in CIViC

BRAF p.Asp594Asn (NM_004333.6:c.1780G>A) causes increased MEK phosphorylation, increased ratio of pERK/ERK, increased signaling through RAF1 (CRAF), it has loss of kinase activity. Class 3 BRAF varian… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

A patient with a metastatic collecting duct carcinoma of the kidney was treated with combination chemotherapy and responded except for one ovarian lesion. A PDX was generated from the ovarian lesion. … (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

A patient with a metastatic collecting duct carcinoma of the kidney was treated with combination chemotherapy and responded except for one ovarian lesion. A PDX was generated from the ovarian lesion. … (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. The melanoma cell line, SK-MEL-208 (BRAF G466E + HRAS Q61K), was sensitive with a low I… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. Lung adenocarcinoma cell lines A549 (KRAS G12S) and CALU-6 (KRAS Q61K) were sensitive w… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. The lung large cell carcinoma cell line, H1299 (NRAS Q61K), was sensitive with a low IC… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Expression of mutant (Q61K) but not wildtype NRAS in the non-small cell lung carcinoma cell line, H1666 (BRAF G466V), resulted in reduced sensitivity to cetuximab as measured by cell growth and RAS-GT… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Expression of mutant (Q61K) but not wildtype NRAS in the non-small cell lung carcinoma cell line, H1666 (BRAF G466V), resulted in reduced sensitivity to cetuximab but not trametinib as measured by cel… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Several BRAF mutant cell lines were treated with vemurafenib, A375 (BRAF V600E) was used as a positive control. The SK-MEL-2 cell line (NRAS Q61R) was not inhibited.

PMID 28783719 · Yao et al., 2017 · Open in CIViC

Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. The lung large cell carcinoma cell line, H661 (PDGFRA amplification), was not sensitive… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R).

PMID 28783719 · Yao et al., 2017 · Open in CIViC

An in vitro kinase assay showed that BRAF D594H, a class 3 BRAF mutation, lacked kinase activity as measured by presence of phosphorylated MEK1/2. RAS-dependent activation of MEK1/2 and ERK1/2 was see… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

BRAF p.Gly469Ala (NM_004333.6:c.1406G>C) causes increased MEK phosphorylation, and increased ratio of pERK/ERK. Class 2 BRAF variant.

PMID 28783719 · Yao et al., 2017 · Open in CIViC

BRAF p.Lys601Glu (NM_004333.6:c.1801A>G) causes increased phosphorylation of substrate of BRAF.

PMID 28783719 · Yao et al., 2017 · Open in CIViC